Trial Profile
An Open-label, Single-arm Phase IV Study of Afatinib in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Who Have Poor Performance Status and Whose Tumors Have the Common Epidermal Growth Factor Receptor (EGFR) Mutations, Exon 19 Deletions or Exon 21(L858R) Substitution Mutations
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ECOG2; ECOG3
- Sponsors Boehringer Ingelheim
- 29 Jun 2017 Status changed from withdrawn prior to enrolment to discontinued.
- 10 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.